A Michigan University clinical researcher allegedly supplied a fund manager with information about drug trial results that the fund used to rake in more than $270 million.
The Scientist
Most Recent
The European Commission approves the Western hemisphere’s first gene therapy, aimed at correcting a lipid-processing disorder.
After two headline successes, companies rush to develop “smart bomb” cancer drugs.
Understanding the mechanism of a classic tuberculosis treatment could refine future strategies for TB drug development.
Reinvestigating a natural antibiotic compound reveals its potential as a tuberculosis drug.
A cheap pain reliever that can kill drug-resistant, tuberculosis-causing bacteria may never be tested.
Doctors question whether a government initiative to speed approval for promising new drugs is ensuring safety.
A phylogenetic study of traditional plant remedies could aid drug development.
A human trial of a hepatitis C treatment is shut down after one of the participants died.
The market for drugs that target rare diseases is expected to rival big pharma blockbusters in the coming decades.
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
